Literature DB >> 29938562

Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients.

Ulrike Heitz1, Martina Papmeyer1,2, Erich Studerus1, Laura Egloff1, Sarah Ittig1, Christina Andreou1, Tobias Vogel3, Stefan Borgwardt4, Marc Graf3, Anne Eckert5, Anita Riecher-Rössler1.   

Abstract

Objectives: Brain-derived neurotrophic factor (BDNF) is involved in numerous cognitive processes. Since cognitive deficits are a core feature of psychotic disorders, the investigation of BDNF levels in psychosis and their correlation with cognition has received increased attention. However, there are no studies investigating BDNF levels in individuals with an at-risk mental state (ARMS) for psychosis. Hence, the aims of the present study were: (1) assessing peripheral BDNF levels across different (potential) stages of psychosis; (2) investigating their association with cognition.
Methods: Plasma and serum BDNF levels and neuropsychological performance were assessed in 16 ARMS, six first-episode psychosis (FEP), and 11 chronic schizophrenia (CS) patients. Neuropsychological assessment covered intelligence, verbal memory, working memory, attention and executive functioning.
Results: Both plasma and serum BDNF levels were highest in CS, intermediate in FEP and lowest in ARMS. Multiple regression analysis revealed a significant positive association of plasma BDNF levels with planning ability across all groups.Conclusions: The lower peripheral BDNF levels in ARMS compared to FEP and CS might point towards an important drop of this neurotrophin prior to the onset of frank psychosis. The associations of peripheral BDNF with planning-abilities match previous findings.

Entities:  

Keywords:  BDNF; blood; neuropsychology; prodromal; psychosis

Year:  2018        PMID: 29938562     DOI: 10.1080/15622975.2018.1462532

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  14 in total

1.  Corticosterone antagonist or TrkB agonist attenuates schizophrenia-like behavior in a mouse model combining Bdnf-e6 deficiency and developmental stress.

Authors:  Yanhui Chen; Shangjin Li; Tianyi Zhang; Feng Yang; Bai Lu
Journal:  iScience       Date:  2022-06-16

2.  Interrelationships Between BDNF, Superoxide Dismutase, and Cognitive Impairment in Drug-Naive First-Episode Patients With Schizophrenia.

Authors:  Mei Hong Xiu; Zezhi Li; Da Chun Chen; Song Chen; Maile E Curbo; Hanjing Emily Wu; Yong Sheng Tong; Shu Ping Tan; Xiang Yang Zhang
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

3.  Effects of BDNF Val66Met genotype and schizophrenia familial risk on a neural functional network for cognitive control in humans.

Authors:  J I Schweiger; E Bilek; A Schäfer; U Braun; C Moessnang; A Harneit; P Post; K Otto; N Romanczuk-Seiferth; S Erk; C Wackerhagen; M Mattheisen; T W Mühleisen; S Cichon; M M Nöthen; J Frank; S H Witt; M Rietschel; A Heinz; H Walter; A Meyer-Lindenberg; H Tost
Journal:  Neuropsychopharmacology       Date:  2018-10-25       Impact factor: 7.853

4.  Mechanism of miR-365 in regulating BDNF-TrkB signal axis of HFD/STZ induced diabetic nephropathy fibrosis and renal function.

Authors:  Peng Zhao; Xiaqiu Li; Yang Li; Jiaying Zhu; Yu Sun; Jianli Hong
Journal:  Int Urol Nephrol       Date:  2021-04-21       Impact factor: 2.370

Review 5.  Brain-derived neurotrophic factor and schizophrenia.

Authors:  Pasquale Di Carlo; Giovanna Punzi; Gianluca Ursini
Journal:  Psychiatr Genet       Date:  2019-10       Impact factor: 2.574

Review 6.  Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain.

Authors:  Magdalena Miranda; Juan Facundo Morici; María Belén Zanoni; Pedro Bekinschtein
Journal:  Front Cell Neurosci       Date:  2019-08-07       Impact factor: 5.505

7.  Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls.

Authors:  Yu-Jie Chiou; Tiao-Lai Huang
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

Review 8.  BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review.

Authors:  Rodrigo R Nieto; Andrea Carrasco; Sebastian Corral; Rolando Castillo; Pablo A Gaspar; M Leonor Bustamante; Hernan Silva
Journal:  Front Psychiatry       Date:  2021-06-16       Impact factor: 4.157

9.  Cognitive and Social Rehabilitation in Schizophrenia-From Neurophysiology to Neuromodulation. Pilot Study.

Authors:  Renata Markiewicz; Beata Dobrowolska
Journal:  Int J Environ Res Public Health       Date:  2020-06-05       Impact factor: 3.390

10.  Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia.

Authors:  Rong-Qin Wu; Chong-Guang Lin; Wei Zhang; Xiao-Dong Lin; Xing-Shi Chen; Ce Chen; Li-Jun Zhang; Zi-Ye Huang; Guang-Dong Chen; Da-Li Xu; Zhi-Guang Lin; Ming-Dao Zhang
Journal:  Chin Med J (Engl)       Date:  2018-10-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.